+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 9 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are conducting a randomized controlled trial to compare survival outcomes between robotic-assisted laparoscopy and open hysterectomy with lymph node assessment for early-stage cervical cancer. The study aims to determine if robotic hysterectomy with tumor containment before colpotomy is not worse than abdominal hysterectomy in terms of disease-free survival. It includes patients with specific cervical cancer stages and tumor sizes suitable for surgery. Participants will undergo either a radical or simple hysterectomy using either traditional open surgery or a robotic-assisted technique. In the robotic group, the vagina is closed before colpotomy, and certain vaginal manipulators are not allowed. Both groups may have salpingectomy and oophorectomy with or without ovarian transposition. Surgeons will document operative details, including any complications, blood loss, and reasons for conversion to open surgery. During the trial, participants will be closely monitored with preoperative assessments like labs, EKG, and MRI to confirm eligibility. Surgical findings and complications will be recorded. The primary outcome measured is survival at 36 months. Participants must provide informed consent and undergo follow-up to assess disease status and survival over the study period, which extends until 2030.

Age: 18Years +FEMALEPhase Not Applicable
156 locations
C

Actively Recruiting

Healthy Volunteer

Researchers are evaluating two approaches to support older adults and their family caregivers during the vulnerable transition from hospital to home. The study compares a patient-centered care transition program alone versus the same program enhanced with special strategies to engage and support family caregivers. This research aims to improve patient safety at home, reduce hospital and emergency visits, and lessen caregiver burden and stress. The study involves two groups one receiving a patient-centered program with assessments, discharge planning, education, and follow-up focused on the patient, and another group receiving these patient strategies plus family caregiver needs assessment, structured education, and skills building. The intervention is delivered through multiple hospitals across five states and uses telephone, video calls, and other technologies to reach participants and families. Participants will be older adults discharged home from hospital and their family caregivers. The study team will assess hospital-free days, patient readmissions, patient ability to do everyday activities, caregiver burden, caregiver self-efficacy, and satisfaction with care transitions. Data will be collected through interviews, questionnaires, and follow-up visits up to 180 days after discharge. The goal is to understand how family involvement affects health outcomes and caregiving experience during this transition period.

Age: 18Years +All GendersPhase Not Applicable
4 locations
P

Actively Recruiting

Researchers are evaluating a treatment approach for early-stage hormone-sensitive, HER-2 negative breast cancer with an Oncotype recurrence score of 18 or less. This Phase III trial compares breast conservation surgery with endocrine therapy alone against breast conservation surgery with both radiation and endocrine therapy. The goal is to see if skipping radiation after lumpectomy is not worse in preventing cancer recurrence in the same breast. Participants will be randomly assigned to one of two groups. One group will receive radiation therapy to the breast plus at least five years of endocrine therapy with drugs such as Tamoxifen, Anastrozole, Letrozole, or Exemestane. The other group will receive endocrine therapy only for at least five years without radiation. Radiation must start within 12 weeks of surgery if assigned. Endocrine therapy dosing and schedule are determined by the treating doctor. During the study, participants will have regular follow-ups up to five years to monitor cancer recurrence in the breast and elsewhere, survival, and breast preservation. Assessments will include clinical exams, imaging like mammograms or MRI, and pathology reviews. The main outcome is time to invasive or noninvasive breast tumor recurrence within five years. Some measures will continue through an average of 15 years, including breast conservation rates. Safety and overall health will be monitored throughout and after treatment.

Age: 50Years - 70YearsAll GendersPhase 3
832 locations
P

Actively Recruiting

Researchers are evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves invasive breast cancer-free survival in premenopausal women with early-stage estrogen receptor-positive, HER2-negative breast cancer and specific recurrence scores. This Phase III trial addresses a critical need for better treatment options in younger women, who face higher risks of breast cancer recurrence and mortality. Participants will receive one of two treatment approaches ovarian function suppression combined with an aromatase inhibitor for five years, or chemotherapy followed by the same hormonal treatment. The choice of chemotherapy, aromatase inhibitor, and ovarian suppression method is determined by the investigator, with options such as goserelin, leuprolide, or triptorelin administered monthly or every three months. Endocrine therapy beyond five years is at the investigators discretion, and bilateral oophorectomy may replace ovarian suppression if desired. During the trial, participants will be monitored for invasive breast cancer-free survival over 11 years following randomization. Additional outcomes include overall survival, disease-free survival, distant recurrence, and treatment-related symptoms such as menopausal effects and pain during aromatase inhibitor therapy. The study involves regular assessments to evaluate these outcomes and ensure participant safety throughout the extended follow-up period.

Age: 18Years - 60YearsFEMALEPhase 3
1276 locations
L

Actively Recruiting

Researchers are evaluating a master screening protocol called Lung-MAP for patients with previously treated non-small cell lung cancer. This phase IIIII trial aims to develop a genomic screening method for large cancer populations and assign participants to appropriate sub-studies based on specific cancer biomarkers. The goal is to compare new targeted therapies designed to block cancer growth or spread with standard care, including sub-studies for patients not eligible for biomarker-driven treatments. The study involves screening patient specimens to determine eligibility for various biomarker-driven or non-matched sub-studies within the Lung-MAP umbrella protocol. This is a screening study without direct interventions instead, patients are assigned to different treatment sub-studies, each operating independently. The protocol also includes an optional ancillary study evaluating attitudes about the return of somatic mutation findings suggestive of germline mutations. Participants provide tumor tissue for biomarker testing, including molecular profiling and PD-L1 analysis, and may submit fresh biopsies and blood samples for circulating tumor DNA testing. Researchers will monitor screening success rates up to three years and collect patient and physician feedback on genetic findings. Participation involves signing informed consent, providing smoking history, and possibly completing surveys. The study duration and assessments vary depending on sub-study assignment and patient progression.

Age: 18Years +All GendersPhase 2Phase 3
1229 locations
E

Actively Recruiting

Researchers are evaluating the combination of osimertinib and bevacizumab versus osimertinib alone as first-line treatment for patients with advanced non-small cell lung cancer NSCLC that has spread beyond the lungs stage IIIB-IV and involves mutations in the EGFR gene. This phase III trial aims to determine if adding bevacizumab, which stops blood vessel growth to tumors, can better control cancer progression and improve survival compared to osimertinib alone. The study also examines overall survival, response rates, central nervous system progression, and treatment toxicity. Participants are randomly assigned to one of two groups one receives oral osimertinib daily, and the other receives oral osimertinib daily plus bevacizumab intravenously every 21 days. Treatment cycles repeat every 21 days unless disease progression or unacceptable side effects occur. Throughout the study, patients undergo various imaging tests including echocardiography, multigated acquisition scans, computed tomography, and possibly magnetic resonance imaging. Blood and urine samples are also collected to study treatment effects and resistance mechanisms. After finishing treatment, participants are monitored every three months for up to 10 years to track disease progression and survival. The main outcome measured is progression-free survival, defined as the time from starting treatment until cancer worsens or death. Secondary outcomes include overall survival, response rates, central nervous system involvement, and treatment safety. Regular assessments and sample collections help researchers understand how the treatments work and their long-term effects.

Age: 18Years +All GendersPhase 3
604 locations
S

Actively Recruiting

Researchers are evaluating whether 6 months of HER2-targeted therapy is as effective as 12 months for treating early-stage HER2-positive breast cancer in patients who have no remaining invasive cancer after preoperative chemotherapy with trastuzumab. The study aims to compare recurrence-free survival and quality of life between shorter and longer treatment durations. Secondary goals include assessing serious side effects, overall survival, local cancer recurrence, and patient-reported symptoms. Participants are randomly assigned to either 6 months or 12 months of HER2-targeted therapy using trastuzumab and possibly pertuzumab, given intravenously or subcutaneously every 21 days. Treatment continues up to 9 or 17 cycles unless disease progresses or side effects are unacceptable. During the trial, participants undergo heart function tests ECHO or MUGA, imaging such as mammography, ultrasound, or MRI, and may provide blood and tissue samples for research. After treatment, participants are followed every 6 months for 5 years or until cancer recurrence, then annually up to 10 years. Researchers monitor recurrence-free survival and quality of life using validated questionnaires. Safety is closely tracked through adverse event reporting, and long-term outcomes including overall survival and brain metastasis occurrence are assessed to understand treatment impact.

Age: 18Years +All GendersPhase 3
702 locations
R

Actively Recruiting

Researchers are evaluating the addition of stereotactic body radiation therapy SBRT to the usual treatment for patients with locally advanced, inoperable non-small cell lung cancer that has spread to nearby tissue or lymph nodes. This phase III trial compares the effect of SBRT combined with conventional image guided radiation therapy IGRT, chemotherapy, and subsequent immunotherapy or targeted therapy to the usual treatment alone. The goal is to see if adding SBRT improves overall survival and progression-free survival. Participants are randomly assigned to one of two groups. Arm I receives conventional IGRT with chemotherapy regimens including paclitaxel, carboplatin, pemetrexed, cisplatin, or etoposide during radiotherapy, followed by consolidation immunotherapy with durvalumab or targeted therapy with osimertinib. Arm II receives SBRT to the primary tumor plus conventional IGRT to nodal metastases along with the same chemotherapy and consolidation treatments. Imaging with CT or PETCT scans is used during follow-up. During the study, participants undergo regular assessments including scans and pulmonary function tests at baseline and at 6 and 12 months after radiation therapy. Researchers also collect patient-reported outcomes and monitor quality of life, adverse events, and changes in lung function over time. Biospecimens and advanced imaging data are collected for further analysis. Participants are followed every 3 months for the first year, then every 6 months for years 2 and 3, and yearly thereafter, for up to 13 years total.

Age: 18Years +All GendersPhase 3
477 locations
R

Actively Recruiting

This trial studies patients with peripheral T-cell lymphoma who have achieved a complete response after initial chemotherapy. It compares the effects of high dose chemotherapy followed by an autologous stem cell transplant using the patients own stem cells to observation only. The trial aims to find out if the transplant improves progression-free survival and overall survival compared to observation alone. This is a phase III randomized study sponsored by the Eastern Cooperative Oncology Group. Participants are randomly assigned to one of two groups. One group receives standard care observation, including regular blood tests, optional bone marrow biopsies, and imaging scans such as CT or PETCT. The other group undergoes stem cell mobilization, leukapheresis to collect stem cells, high dose chemotherapy, and then an autologous stem cell transplant. Both groups have similar monitoring with blood samples and imaging throughout the study. Participants are followed closely after treatment every 3 months for 2 years, then every 6 months for 3 years, and annually up to 7 years, totaling 12 years from randomization. The study measures progression-free survival as the primary outcome, with overall survival, relapse rates, and mortality as secondary outcomes. Monitoring includes blood samples, optional bone marrow tests, and imaging to track disease status and safety over time.

Age: 18Years - 75YearsAll GendersPhase 3
165 locations